Vaccine showed 100% efficacy against coronavirus in 12 to 15-year-olds; Pfizer BioNTech

The chief executive of German company BioNTech, Ugur Sahin, said the results showing high protection for teens were “very encouraging".

The BioNTech-Pfizer shot is based on novel mRNA technology and was the first COVID-19 vaccine to be approved in the West late last year.

Both the United States and the European Union have approved its use for people aged 16 and above.

Since then, it has been used in millions of adults in more than 65 countries.

BioNTech said on Tuesday it was on track to manufacture 2.5 billion doses of its vaccine this year.

Children from agr 2 to 5 are expected to get their first dose next week in the study which will also cover children as young as six months old.